moxifloxacin has been researched along with cryptotanshinone in 1 studies
| Studies (moxifloxacin) | Trials (moxifloxacin) | Recent Studies (post-2010) (moxifloxacin) | Studies (cryptotanshinone) | Trials (cryptotanshinone) | Recent Studies (post-2010) (cryptotanshinone) |
|---|---|---|---|---|---|
| 3,157 | 552 | 1,690 | 370 | 0 | 268 |
| Protein | Taxonomy | moxifloxacin (IC50) | cryptotanshinone (IC50) |
|---|---|---|---|
| Chain A, RNA-directed RNA polymerase NS5 | Dengue virus 2 16681-PDK53 | 90.06 | |
| Lysine-specific histone demethylase 1A | Homo sapiens (human) | 9.02 | |
| Replicase polyprotein 1a | Severe acute respiratory syndrome-related coronavirus | 0.8 | |
| Replicase polyprotein 1ab | Severe acute respiratory syndrome coronavirus 2 | 3.722 | |
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | 10 | |
| Signal transducer and activator of transcription 3 | Homo sapiens (human) | 4.6 | |
| Tryptophan 2,3-dioxygenase | Homo sapiens (human) | 9.8 | |
| Hypoxia-inducible factor 1-alpha | Homo sapiens (human) | 1.47 | |
| Endothelial PAS domain-containing protein 1 | Homo sapiens (human) | 1.47 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 1 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, J; Gao, K; Huang, F; Tepe, JJ; Wang, R; Wei, GW | 1 |
1 other study(ies) available for moxifloxacin and cryptotanshinone
| Article | Year |
|---|---|
Perspectives on SARS-CoV-2 Main Protease Inhibitors.
Topics: Antiviral Agents; Coronavirus 3C Proteases; Humans; Protease Inhibitors | 2021 |